// App-Quantinova.ai

1439 : OrthoCARs: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell antitumorefficacy

Researchers

Presenter

  • Paul-Joseph Aspuria

Principal Investigators

  • Michael A Bauer

  • Sandro vivona

  • Rene de Waal Malefyt

  • Rob Kastelein

  • Martin Oft

  • Jan Emmerich

  • Deepti Rokkam

  • Steven E Kauder

  • Scott McCauley

  • Romina Riener

  • Rakesh Verma

Medical Centers

  • Synthekine, Menlo Park, CA

  • Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR

  • ARMO BioSciences, Redwood City, CA

  • Alexo Therapeutics Inc., South San Francisco, CA

  • Lilly, Redwood City, CA

  • MMCRI, Maine Medical Center, New Haven, CT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Lymphomas

Biomarkers

  • Natural Killer cells

  • Breakpoint Cluster Region

  • Cluster of Differentiation 19

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

  • Coxsackie Virus And Adenovirus Receptor

  • Interleukin-2

Drug/Treatment

  • Interleukin

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Dose Escalation

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved